TY  - JOUR
T1  - FIlling in the pieces of the sleep apnea–hypertension puzzle
AU  - Kapur VK, Weaver EM
Y1  - 2012/05/23
N1  - 10.1001/jama.2012.5039
JO  - JAMA
SP  - 2197
EP  - 2198
VL  - 307
IS  - 20
N2  - 
Obstructive sleep apnea (OSA) is a common but underdiagnosed disorder that is associated with excessive sleepiness, poor quality of life, neurocognitive deficits, metabolic dysfunction, cardiovascular disease, and early mortality. Continuous positive airway pressure (CPAP) therapy efficaciously ameliorates obstructed breathing events.1 Randomized controlled trials (RCTs) show that CPAP therapy reduces sleepiness and improves quality of life in patients with moderate and severe OSA.2 A number of difficulties have complicated the assessment of the causal link between OSA and hypertension, including multiple shared risk factors, differential susceptibility of subgroups to the deleterious effects of OSA, and the challenges of conducting definitive RCTs. Despite these barriers, a significant evidence base has developed to support the identification and treatment of OSA in patients with hypertension. Multiple hypertension guidelines recognize OSA as a secondary cause of hypertension and specifically advise assessment and treatment of OSA in patients with refractory hypertension.3- 5

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.5039
UR  - http://dx.doi.org/10.1001/jama.2012.5039
ER  -